The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

Butler, J. et al. (2017) The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure, 19(11), pp. 1390-1400. (doi:10.1002/ejhf.933) (PMID:28836359)

146845.pdf - Accepted Version



Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 32% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate.

Item Type:Articles
Keywords:Cardiology and cardiovascular medicine.
Glasgow Author(s) Enlighten ID:Sattar, Professor Naveed
Authors: Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., Kaul, S., Lam, C. S.P., Lip, G. Y.H., Marx, N., McCullough, P. A., Mehta, C. R., Ponikowski, P., Rosenstock, J., Sattar, N., Salsali, A., Scirica, B. M., Shah, S. J., Tsutsui, H., Verma, S., Wanner, C., Woerle, H.-J., Zannad, F., and Anker, S. D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:European Journal of Heart Failure
ISSN (Online):1879-0844
Published Online:24 August 2017
Copyright Holders:Copyright © 2017 The Authors and European Society of Cardiology
First Published:First published in European Journal of Heart Failure 19(11): 1390-1400
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record